Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis
Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full |
| _version_ | 1818886930959433728 |
|---|---|
| author | Ayiguli Abudukeremu Canxia Huang Hongwei Li Runlu Sun Runlu Sun Xiao Liu Xiao Liu Xiaoying Wu Xiaoying Wu Xiangkun Xie Xiangkun Xie Jingjing Huang Jingjing Huang Jie Zhang Jie Zhang Jinlan Bao Yuling Zhang Yuling Zhang |
| author_facet | Ayiguli Abudukeremu Canxia Huang Hongwei Li Runlu Sun Runlu Sun Xiao Liu Xiao Liu Xiaoying Wu Xiaoying Wu Xiangkun Xie Xiangkun Xie Jingjing Huang Jingjing Huang Jie Zhang Jie Zhang Jinlan Bao Yuling Zhang Yuling Zhang |
| author_sort | Ayiguli Abudukeremu |
| collection | DOAJ |
| description | Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA-1 replacement therapies on atherosclerotic lesions both in humans and mice.Methods: The PubMed, Cochrane Library, Web of Science, and EMBASE databases were searched through June 6, 2020. The methodological quality of the human studies was assessed using Review Manager (RevMan, version 5.3.). The methodological quality of the mouse studies was assessed using a stair list. STATA (version 14.0) was used to perform all statistical analyses.Results: Fifteen randomized controlled human trials and 17 animal studies were included. The pooled results showed that HDL/apoA-1 replacement therapy use did not significantly decrease the percent atheroma volume (p = 0.766) or total atheroma volume (p = 0.510) in acute coronary syndrome (ACS) patients (N = 754). However, HDL/apoA-1 replacement therapies were significantly associated with the final percent lesion area, final lesion area, and changes in lesion area (SMD, −1.75; 95% CI: −2.21~-1.29, p = 0.000; SMD, −0.78; 95% CI: −1.18~-0.38, p = 0.000; SMD: −2.06; 95% CI, −3.92~-0.2, p = 0.03, respectively) in mice.Conclusions: HDL/apoA-1 replacement therapies are safe but do not significantly improve arterial atheroma volume in humans. The results in animals suggest that HDL/apoA-1 replacement therapies decrease the lesion area. Additional studies are needed to investigate and explain the differences in HDL/apoA-1 replacement therapy efficacies between humans and animals.Trial registration number: Human pooled analysis: PROSPERO, CRD42020210772. prospectively registered. |
| first_indexed | 2024-12-19T16:29:10Z |
| format | Article |
| id | doaj.art-87ee656023c94e079d56f4c28c7b8c4c |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-19T16:29:10Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-87ee656023c94e079d56f4c28c7b8c4c2022-12-21T20:14:16ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-08-01810.3389/fcvm.2021.700233700233Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-AnalysisAyiguli Abudukeremu0Canxia Huang1Hongwei Li2Runlu Sun3Runlu Sun4Xiao Liu5Xiao Liu6Xiaoying Wu7Xiaoying Wu8Xiangkun Xie9Xiangkun Xie10Jingjing Huang11Jingjing Huang12Jie Zhang13Jie Zhang14Jinlan Bao15Yuling Zhang16Yuling Zhang17Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaCritical Care Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaComprehensive Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaBackground: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA-1 replacement therapies on atherosclerotic lesions both in humans and mice.Methods: The PubMed, Cochrane Library, Web of Science, and EMBASE databases were searched through June 6, 2020. The methodological quality of the human studies was assessed using Review Manager (RevMan, version 5.3.). The methodological quality of the mouse studies was assessed using a stair list. STATA (version 14.0) was used to perform all statistical analyses.Results: Fifteen randomized controlled human trials and 17 animal studies were included. The pooled results showed that HDL/apoA-1 replacement therapy use did not significantly decrease the percent atheroma volume (p = 0.766) or total atheroma volume (p = 0.510) in acute coronary syndrome (ACS) patients (N = 754). However, HDL/apoA-1 replacement therapies were significantly associated with the final percent lesion area, final lesion area, and changes in lesion area (SMD, −1.75; 95% CI: −2.21~-1.29, p = 0.000; SMD, −0.78; 95% CI: −1.18~-0.38, p = 0.000; SMD: −2.06; 95% CI, −3.92~-0.2, p = 0.03, respectively) in mice.Conclusions: HDL/apoA-1 replacement therapies are safe but do not significantly improve arterial atheroma volume in humans. The results in animals suggest that HDL/apoA-1 replacement therapies decrease the lesion area. Additional studies are needed to investigate and explain the differences in HDL/apoA-1 replacement therapy efficacies between humans and animals.Trial registration number: Human pooled analysis: PROSPERO, CRD42020210772. prospectively registered.https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/fulllipoproteinsHDLapolipoprotein A-Imimeticatherosclerosis |
| spellingShingle | Ayiguli Abudukeremu Canxia Huang Hongwei Li Runlu Sun Runlu Sun Xiao Liu Xiao Liu Xiaoying Wu Xiaoying Wu Xiangkun Xie Xiangkun Xie Jingjing Huang Jingjing Huang Jie Zhang Jie Zhang Jinlan Bao Yuling Zhang Yuling Zhang Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis Frontiers in Cardiovascular Medicine lipoproteins HDL apolipoprotein A-I mimetic atherosclerosis |
| title | Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis |
| title_full | Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis |
| title_short | Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis |
| title_sort | efficacy and safety of high density lipoprotein apolipoprotein a1 replacement therapy in humans and mice with atherosclerosis a systematic review and meta analysis |
| topic | lipoproteins HDL apolipoprotein A-I mimetic atherosclerosis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full |
| work_keys_str_mv | AT ayiguliabudukeremu efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT canxiahuang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT hongweili efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT runlusun efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT runlusun efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiaoliu efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiaoliu efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiaoyingwu efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiaoyingwu efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiangkunxie efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT xiangkunxie efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT jingjinghuang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT jingjinghuang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT jiezhang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT jiezhang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT jinlanbao efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT yulingzhang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis AT yulingzhang efficacyandsafetyofhighdensitylipoproteinapolipoproteina1replacementtherapyinhumansandmicewithatherosclerosisasystematicreviewandmetaanalysis |